FDA ruling to trigger royalty payments for Novo Nordisk
The FDA has just approved a drug licensed by Forma Therapeutics, which Novo Nordisk acquired in September. Royalties from the newly approved cancer treatment will total 13-35% of sales.
by albert rønning-andersson, translated by catherine brett
Novo Nordisk’s acquisition of Forma Therapeutics, which was completed in September, is already turning out to be a pretty good deal for the former.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk completes Forma Therapeutics acquisition
For subscribers
